A boost in biosimilars sales provided only minor consolation to Biogen in 2020, as generic competition to its blockbuster Tecfidera (dimethyl fumarate) multiple sclerosis brand in the US late in the year took a bite out of the company’s annual sales, which fell by 6% to $13.4bn.
“Biosimilars delivered solid performance despite continued COVID-19 impact, with revenues of $796m for 2020 which represents 8% growth
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?